Compare Danaher Corporation (DHR) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Kyndryl Holdings Inc — how do they compare? Danaher Corporation trades at $217.88 (market cap $153.60B), while Kyndryl Holdings Inc trades at $11.86 (market cap $2.49B). The key difference: Danaher Corporation is far larger — about 61.7× Kyndryl Holdings Inc's market cap, and Danaher Corporation pays a 0.73% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Kyndryl Holdings Inc for 36 Days on average.
| DHR | KD | |
|---|---|---|
Market Cap | $153.60B | $2.49B |
Volume | 3,974,063 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $242.05 | $29.76 |
52-Week Low | $161.91 | $10.59 |
Typical Hold Time | 69 Days | 36 Days |
Enterprise Value | $175.81B | $5.32B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Kyndryl (KD) trades at $11.88, up 3.48% today, with a bearish technical signal and mixed earnings. Revenue declined to $15.06B in 2025, but net income turned positive at $252M, marking a recovery from prior losses. The company is actively investing in AI, as highlighted by recent news of an AI innovation lab and acquisitions. Analyst consensus is mostly hold, with a $14.67 price target suggesting moderate upside.
The outlook hinges on AI-driven growth offsetting revenue pressures, but risks include high debt, competitive IT services market, and inconsistent earnings. Institutional sentiment is cautious, with weak technical trends near key support. Upside depends on execution of modernization contracts and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
